Nail psoriasis: A retrospective study on the effectiveness of systemic treatments (classical and biological therapy)

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 5, 2011, Pages 579-586

  Sanchez Regana M ^a   Sola Ortigosa, J ^a   Alsina Gibert, M ^b   Vidal Fernandez M ^c   Umbert Millet, P ^a  

^a HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Clever Instruments SL   (Spain)

Author keywords

biological therapy; nail psoriasis; systemic treatment; treatment

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; USTEKINUMAB;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NAIL PSORIASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; PUVA; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE; SYSTEMIC THERAPY; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION;

EID: 79954621230     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03938.x     Document Type: Article

References (30)

1. De Jong EMGJ, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1728 patients. Dermatology 1996; 193: 300-303.
2. Tosti A, Morelli R, Bardazzi F, et al. Psoriasis of the nails. In, Dubertret L, ed. Psoriasis. ISED, Brescia, 1994: 201-207.
3. Sadek HA, Abdel-Nasser AM, El-Amawy TA, et al. Rheumatic manifestations of psoriasis. Clin Rheumatol 2007; 26: 488-498. (Pubitemid 46370410)
4. Sanchez-Regaña M, Umbert P,. Aspectos diagnõsticos y terapéuticos de la psoriasis ungueal. Actas Dermosifiliogr 2008; 99: 34-43. (Pubitemid 351239803)
5. Rich P, Scher RK,. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49: 206-212. (Pubitemid 36951265)
6. De Berker D,. Management of psoriatic nail disease. Semin Cutan Med Surg 2009; 28: 39-43.
7. Duhard-Brohan E,. Psoriasis ungueal. Ann Dermatol Venereol 1999; 126: 445-449. (Pubitemid 29336661)
8. Piraccini BM, Tosti A, Iorizzo M, et al. Pustular psoriasis of the nails: treatment and long-term follow-up of 46 patients. Br J Dermatol 2001; 144: 1000-1005.
9. Tosti A, Ricotti C, Romanelli P, et al. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009; 145: 269-271.
10. Lee JY,. Severe 20-nail psoriasis successfully treated by low dose methotrexate. Dermatol Online J 2009; 15: 8.
11. Ojeda R, Sanchez Regaña M, Massana J, et al. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study. J Dermatol Treat 2005; 16: 338-341.
12. Mahrle G, Schulze HJ, Faerber L, et al. Low-dose short-term cyclosporin versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995; 32: 78-88.
13. Marx JL, Scher RK,. Response of psoriatic nails to oral photochemotherapy. Arch Dermatol 1980; 116: 1023-1024. (Pubitemid 11199413)
14. Reich K, Nestle FO, Papp K, et al. EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374. (Pubitemid 41443403)
15. Rigopoulos D, Gregoriou S, Stratigos A, et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol 2008; 159: 453-456. (Pubitemid 352009870)
16. Fabroni C, Gori A, Troiano M, et al. Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients. J Eur Acad Dermatol Venereol 2010;.
17. Reich K,. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol 2009; 23: 15-21.
18. Noiles K, Vender R,. Nail psoriasis and biologics. J Cutan Med Surg 2009; 13: 1-5.
19. Hussain W, Coulson I, Owen C,. Severe recalcitrant nail psoriasis responding dramatically to infliximab: report of two patients. Clin Exp Dermatol 2008; 33: 520-522. (Pubitemid 351832149)
20. Lamerson C, Stevens G, Sax K,. Treatment of nail psoriasis with efalizumab: a preliminary study. Cutis 2008; 82: 217-220.
21. Katsambas A, Peris K, Vena G, et al. Assessing the impact of efalizumab on nail, scalp and palmoplantar psoriasis and on quality of life: Results from a multicentre, open-label, phase IIIb/IV trial. Arch Drug Inf 2009; 2: 66-70.
22. Luger TA, Barker J, Lambert J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009; 23: 896-904.
23. Barrera MV, Habicheyn S, Mendiola MV, et al. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur J Dermatol 2008; 18: 683-687.
24. Rallis E, Stavropoulou E, Rigopoulos D, et al. Rapid response of nail psoriasis to etanercept. J Rheumatol 2008; 35: 544-545. (Pubitemid 351374441)
25. Van den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010; 69: 394-399.
26. Rigopoulos D, Gregoriou S, Lazaridou E, et al. Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol 2010; 24: 530-534.
27. Gupta AK, Lynde CW, Jain HC, et al. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. Br J Dermatol 1997; 136: 786-789. (Pubitemid 27278095)
28. Sanchez Regaña M, Videla S, Villoria J, et al. Prevalence of fungal involvement in a series of patients with psoriasis. Clin Exp Dermatol 2008; 33: 194-195. (Pubitemid 351197189)
29. Sais G, Jucglà A, Peyri J,. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol 1995; 132: 758-761.
30. Vender RB, Lynde CW, Poulin Y,. Prevalence and epidemiology of onychomycosis. J Cutan Med Surg 2006; 10: S28-S33.